Transcription Active Complex Targeting Cancer Drug From Viral Protein Sequence

Tech ID: 33316 / UC Case 2020-557-0


Researchers at the University of California, Davis have developed a viral peptide therapeutic that targets MYC-based cancerous tumors.

Full Description

Researchers at the University of California Davis have developed a cancer therapeutic based on an oncogenic virus. This treatment directly inhibits cancerous gene expression, preventing the genes from replicating. Thus, MYC-based tumors are targeted and destroyed. The drug has also shown impressive results in eliminating lymphomas in xenograft studies on mice, killing the cancer cells without any toxicity to the host.


  • Treatment of MYC-based cancers, such as lymphoma and carcinoma 
  • Potential application in combination with existing cancer drugs and antibody-based drugs to increase the latter's efficacy


  • The first drug to specifically and effectively target MYC pathways 
  • Low toxicity to the host being treated 
  • Can be combined with existing cancer drugs and antibody-based drugs to improve efficacy 
  • Opens avenues for applying virology in developing future cancer treatments

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20230382953 11/30/2023 2020-557


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Izumiya, Yoshihiro
  • Shimoda, Michiko

Other Information


cancer therapeutic, MYC, viral oncology, viral peptide sequencing, oncology, peptide

Categorized As